Advanced breast cancer (ABC)  aromatase inhibitors (AIs)  everolimus (EVE)  fulvestrant (FUL)  retrospective study  

AIs  aromatase inhibitors  AMPK  Adenosine Monophosphate-Activated Protein Kinase  AR  androgen  ATM  Ataxia Telangiectasia Mutated  ATP  Adenosine Triphosphate  BCSS  breast cancer specific survival  CK-MB  Creatine Kinase-MB  CREB1  cAMP Response Element-Binding Protein 1  CSC  cancer stem cell  DFS  disease-free survival  DHFU  dihydrofluorouracil  DPD  dihydropyrimidine dehydrogenase  EpCAM  Epithelial Cell Adhesion Molecule  ER  estrogen  ERCC1  excision repair cross-complementary 1  ERK  extracellular signal-regulated kinases  EZH2  enhancer of zeste homolog 2  FdUMP  fluorodeoxyuridine monophosphate  FdUTP  fluorodeoxyuridine triphosphate  FHC  ferritin heavy chain  FUTP  fluorouridine triphosphate  HbA1C  hemoglobin A1c  HER  Human Epidermal Growth Factor Receptor  HIF-1α  hypoxia-inducible factor-1α  HK  hexokinase  IGF1R  insulin growth factor 1 receptor  LDH  lactate dehydrogenase  MDA  Muscular Dystrophy Association  MMP  Matrix Metallopeptidase  MRP1  multidrug resistance-associated protein 1  mTOR  mammalian target of rapamycin  MTX  methotrexate  NCCN  National Comprehensive Cancer Network  OS  overall survival  pCR  Pathologic Complete Response  PDGFR  platelet-derived growth factor receptors  PFS  progression-free survival  PKA  protein kinase A  PR  progesterone receptor  RFS  relapse-free survival  SOD  superoxide dismutase  TAM  tamoxifen  TCA  tricarboxlic acid  TS  thymidylate synthase  Combination  Mechanisms  Metformin  Chemotherapeutic drugs